No Data
No Data
GSK Settles Majority Of Zantac Lawsuits, But Pipeline Doubts Remain
Express News | AstraZeneca PLC Reports 9.9% Passive Stake in Conduit Pharmaceuticals Inc as of August 7 - SEC Filing
Astrazeneca (AZN.US) antibody new drug new indications have been accepted for listing application in China.
Astrazeneca (AZN.US) new antibody drug and new indications have been accepted for market application in China.
AstraZeneca Target Cut to GBP120 From GBP140 by Intron Health
AstraZeneca Cut to Hold From Buy by Intron Health
BenevolentAI to Present on Explainable AI for Drug Discovery at BioTechX Europe 2024
No Data
No Data